Product Description: Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells[1] [2] [3] [4] [5] [6].
Applications: Cancer-programmed cell death
Formula: C11H16N4O4
Citations: Adv Sci (Weinh). 2023 Mar 26;e2206007./Biochem Pharmacol. 2024 Apr 30:224:116247./Biomed Pharmacother. 2022 Jun 17;153:113280./Cardiovasc Toxicol. 2024 Jun 19./Eur J Med Chem. 2024 Nov 26:283:117108./Free Radic Biol Med. 2020 Nov 20;160:303-318./Free Radic Biol Med. 2024 Dec 9:227:296-311./Mol Med Rep. 2024 May;29(5):84./Nano Res. 2023 Apr 18./Phytomedicine. 2023 Jun 10, 154922./Environ Toxicol Pharmacol. 2023 Sep 7;104261./Nat Med. 2016 May;22(5):547-56.
References: [1]Rahimi P, et al. Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines. Cureus. 2023 Apr 8;15(4):e37308./[2]Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007 Jul;151(6):771-8./[3]de Baat EC, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022 Dec;6(12):885-894./[4]Deng S, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172(9):2246-57./[5]Mei M, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1;160:107758./[6]Zhang H, et al. Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021 Jul 14;8:685434. doi: 10.3389/fcvm.2021.685434.
CAS Number: 24584-09-6
Molecular Weight: 268.27
Compound Purity: 99.88
Research Area: Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Solubility: DMSO : 25 mg/mL (ultrasonic)
Target: Apoptosis;Ferroptosis
Deutsch
English
